Harmony Biosciences price to book ratio HRMY
Market value divided by the book value of the company's net assets, since 2020.
- Today, Nov 2, 2026
- 2.2×
- 6-year median
- 4.0×
- Against its 6-year history
- 8th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 1.8× to 28.7×
- Peer median
- 3.0×
Harmony Biosciences' price to book ratio is 2.2× as of Nov 2, 2026.
That is below its 6-year median of 4.0×, lower than on 92% of days in the last 6 years.
Over that time it ranged from 1.8× in Mar 2026 to 28.7× in Dec 2020.
The median for 10 large drugmakers of a similar size is 3.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.2× | 1.8× | 2.7× |
| 2025 | 2.6× | 1.9× | 3.7× |
| 2024 | 3.3× | 3.1× | 4.1× |
| 2023 | 3.9× | 2.4× | 9.3× |
| 2022 | 9.5× | 9.5× | 16.3× |
| 2021 | 16.4× | 13.7× | 24.1× |
| 2020 | 21.8× | 21.5× | 28.7× |
Against its peers
Companies in Drug Manufacturers - General nearest Harmony Biosciences' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| HRMYHarmony Biosciences | 2.2× |
| PBHPrestige Consumer Healthcare | 1.2× |
| NRIXNurix Therapeutics | 2.9× |
| ANIPANI Pharmaceuticals | 2.7× |
| PAHCPhibro Animal Health | 4.1× |
| PCRXPacira BioSciences | 2.2× |
| ANABAnaptysbio | 132× |
| OGNOrganon | 3.0× |
| LQDALiquidia | 19.2× |
| OMEROmeros | n/m |
| ARQTArcutis Biotherapeutics | 17.8× |
| Peer median | 3.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Harmony Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.